Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Wen Jia Zuo"'
Autor:
Wen-Jia Zuo, Li Chen, Yu Shen, Zhong-Hua Wang, Guang-Yu Liu, Ke-Da Yu, Gen-Hong Di, Jiong Wu, Jun-Jie Li, Zhi-Ming Shao
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: With our growing insight into the molecular heterogeneity and biological characteristics of breast cancer, individualized treatment is the future of cancer treatment. In this prospective Fudan University Shanghai Cancer Center Breast Canc
Externí odkaz:
https://doaj.org/article/0d7935c7ecb74a46860ea61e0ae9fa69
Autor:
Min He, Jun‐Jie Li, Wen‐Jia Zuo, Lei Ji, Yi‐Zhou Jiang, Xi‐Chun Hu, Zhong‐Hua Wang, Zhi‐Ming Shao
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6212-6220 (2019)
Abstract Background Endocrine therapy is the preferred treatment for patients with hormone receptor ‐positive metastatic breast cancer (MBC). While visceral metastasis is a negative prognostic factor, few studies have distinguished between the prog
Externí odkaz:
https://doaj.org/article/8cb8cbdeaef841a3837206943b6af6e1
Autor:
Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiu-Wei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu, Yi-Zhou Jiang, Zhong-Hua Wang, Zhi-Ming Shao
Publikováno v:
Cell Research. 33:389-402
Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we report the final results of FUTURE, a phase II umbrella
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88a03c035497f74cae720707b5960ef6
https://doi.org/10.1038/s41422-023-00795-2
https://doi.org/10.1038/s41422-023-00795-2
Publikováno v:
Cancer Research. 83:P1-11
Background: The effect of neoadjuvant therapy on tumor downstaging and breast-conserving during surgery is well documented. Pathologic complete response (pCR) after neoadjuvant treatment was associated with long-term survival. HLX02 (Zercepac®), a b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1a3933ff790cd9fdc85d1e01aa6ef4c
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-20
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-20
Autor:
Zhi-Ming Shao, Zhong-Hua Wang, Yi-Zhou Jiang, Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu
Publikováno v:
Cancer Research. 83:OT3-27
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes (luminal androgen receptor [LAR], immunomodulatory [IM], basal-like immune-suppressed [B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::411e1a8367a9e5898e5df66fb94a01c7
https://doi.org/10.1158/1538-7445.sabcs22-ot3-27-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-27-01
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background and PurposeAlthough tumor size and nodal status are the most important prognostic factors, it is believed that nodal status outperforms tumor size as a prognostic factor. In particular, when patients have a nodal stage greater than N2 (mor
Externí odkaz:
https://doaj.org/article/a940843b8eea4bef8c8dcf503932500a
Autor:
Li Chen, Liu Yang, Ling Yao, Xia-Ying Kuang, Wen-Jia Zuo, Shan Li, Feng Qiao, Yi-Rong Liu, Zhi-Gang Cao, Shu-Ling Zhou, Xiao-Yan Zhou, Wen-Tao Yang, Jin-Xiu Shi, Wei Huang, Xin Hu, Zhi-Ming Shao
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-17 (2018)
The PI3K pathway is altered across various cancer types. Here the authors use amplicon exon sequencing to analyze the landscape of somatic mutations affecting the PI3K pathway specifically in breast cancer patients in China.
Externí odkaz:
https://doaj.org/article/35be9cbfd9d943158a629a540eb68b22
Supplementary Data from PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression
Autor:
Zhi-Ming Shao, Xin Hu, Peng Wang, Da-Qiang Li, Wen-Jia Zuo, Ling Yao, Hai-Yun Zhao, Wei-Li Sun, Bi Lian, Hong-Yan Xie, Feng Qiao, Yi-Rong Liu, Yue Gong, Ding Ma, Xiao-Guang Li, Hong-Jie Shen, Meng-Zhu Xue, Yi-Zi Zheng
Fig. S1. RNA-seq based RBP Library construction and CRISPR screen reveals RBP hits related to tumor growth and metastasis. Fig. S2. PHF5A is frequently up-regulated in breast cancer, associated with poor clinical outcome, and essential for cancer cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e0b2e19dd6bb3f536516f529bd4135
https://doi.org/10.1158/0008-5472.22420092
https://doi.org/10.1158/0008-5472.22420092
Autor:
Zhi-Ming Shao, Ke-Da Yu, Gen-Hong Di, Jiong Wu, Guang-Yu Liu, Xin Hu, Xiao-En Xu, Yu-Jie Wang, Yi-Zhou Jiang, Wen-Jia Zuo
Supplementary Figure S1. Flowchart of study design. Supplementary Figure S2. Protein structure visualizations of the HER2 somatic mutations. Supplementary Figure S3. HER2 mutations L768S and V773L induce HER2 internalization. Supplementary Figure S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3f91717d1d656c71f509d4d9b678d1
https://doi.org/10.1158/1078-0432.22467669.v1
https://doi.org/10.1158/1078-0432.22467669.v1
Autor:
Zhi-Ming Shao, Ke-Da Yu, Gen-Hong Di, Jiong Wu, Guang-Yu Liu, Xin Hu, Xiao-En Xu, Yu-Jie Wang, Yi-Zhou Jiang, Wen-Jia Zuo
Supplementary Methods: Immunofluorescence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c422f8d5d0126c3ff666c69f0602030a
https://doi.org/10.1158/1078-0432.22467666
https://doi.org/10.1158/1078-0432.22467666